MX338758B - Anticuerpos monoclonales humanos, derivados de celulas b humanas, y que tienen actividad neutralizante contra el virus de la influenza a. - Google Patents
Anticuerpos monoclonales humanos, derivados de celulas b humanas, y que tienen actividad neutralizante contra el virus de la influenza a.Info
- Publication number
- MX338758B MX338758B MX2012010406A MX2012010406A MX338758B MX 338758 B MX338758 B MX 338758B MX 2012010406 A MX2012010406 A MX 2012010406A MX 2012010406 A MX2012010406 A MX 2012010406A MX 338758 B MX338758 B MX 338758B
- Authority
- MX
- Mexico
- Prior art keywords
- human
- seq
- cells
- derived
- sequence
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—RNA viruses
- C07K16/108—Orthomyxoviridae (F), e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/11—Orthomyxoviridae, e.g. influenza virus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
Abstract
La presente invención se refiere a un anticuerpo monoclonal contra el virus de la influenza A, que comprende una cadena liviana que comprende una región CDR1 que comprende una secuencia de SEQ ID NO.7, una región CDR2 que comprende una secuencia de SEQ ID NO. 2, y una región CDR3 que comprende una secuencia de SEQ ID NO.8; y una cadena pesada que comprende una región CDR1 que comprende una secuencia de SEQ ID NO.9; una región CDR2 que comprende una secuencia de SEQ ID NO. 10, SEQ ID NO. 10 y una región CDR3 que comprende una secuencia de SEQ ID NO. 11.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20100020587 | 2010-03-08 | ||
| PCT/KR2011/001563 WO2011111966A2 (en) | 2010-03-08 | 2011-03-07 | Human monoclonal antibodies derived from human b cells and having neutralizing activity against influenza a viruses |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2012010406A MX2012010406A (es) | 2012-10-03 |
| MX338758B true MX338758B (es) | 2016-04-29 |
Family
ID=44563977
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012010406A MX338758B (es) | 2010-03-08 | 2011-03-07 | Anticuerpos monoclonales humanos, derivados de celulas b humanas, y que tienen actividad neutralizante contra el virus de la influenza a. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9573991B2 (es) |
| EP (3) | EP3098236A1 (es) |
| JP (1) | JP5795340B2 (es) |
| KR (1) | KR101297784B1 (es) |
| CN (1) | CN102791734B (es) |
| AU (2) | AU2011225044B2 (es) |
| CA (2) | CA2790949C (es) |
| EA (2) | EA021977B1 (es) |
| IL (1) | IL221760A (es) |
| MX (1) | MX338758B (es) |
| WO (1) | WO2011111966A2 (es) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2787099A1 (en) | 2009-03-30 | 2010-10-14 | Anice C. Lowen | Influenza virus hemagglutinin polypeptides containing stem domains, vaccines and uses thereof |
| US9701723B2 (en) | 2010-02-18 | 2017-07-11 | Icahn School Of Medicine At Mount Sinai | Vaccines for use in the prophylaxis and treatment of influenza virus disease |
| CN102939103A (zh) | 2010-03-30 | 2013-02-20 | 西奈山医学院 | 流感病毒疫苗及其应用 |
| KR20140068205A (ko) * | 2011-09-20 | 2014-06-05 | 마운트 시나이 스쿨 오브 메디슨 | 인플루엔자 바이러스 백신 및 이의 용도 |
| CA2850720C (en) | 2011-09-30 | 2016-03-29 | Celltrion Inc. | Binding molecule having influenza a virus-neutralizing activity produced from human b cell |
| KR20130059721A (ko) * | 2011-11-29 | 2013-06-07 | (주)셀트리온 | 인간 ｂ 세포에서 생산된 인플루엔자 ａ 바이러스 중화 활성을 가지는 결합 분자 |
| JP6325451B2 (ja) | 2011-12-02 | 2018-05-16 | アイム・セラピューティクス・べー・フェー | Ａ型インフルエンザに特異的な抗体 |
| WO2013089496A1 (ko) * | 2011-12-15 | 2013-06-20 | (주)에이프로젠 | H1n1-감염된 환자들로부터 유도된 매우 잠재력 있는 넓은-스펙트럼 중화 단일클론 항체 및 이를 포함하는 바이러스의 치료용 조성물 |
| US9969794B2 (en) | 2012-05-10 | 2018-05-15 | Visterra, Inc. | HA binding agents |
| US9834594B2 (en) * | 2012-09-07 | 2017-12-05 | Celltrion, Inc. | Human monoclonal antibodies derived from human B cells and having neutralizing activity against influenza A viruses |
| AU2013345072B2 (en) | 2012-11-13 | 2017-12-07 | Genentech, Inc. | Anti-hemagglutinin antibodies and methods of use |
| KR20150104117A (ko) | 2012-12-18 | 2015-09-14 | 이칸 스쿨 오브 메디슨 엣 마운트 시나이 | 인플루엔자 바이러스 백신 및 그의 용도 |
| WO2014159960A1 (en) | 2013-03-14 | 2014-10-02 | Icahn School Of Medicine At Mount Sinai | Antibodies against influenza virus hemagglutinin and uses thereof |
| KR20140118682A (ko) * | 2013-03-29 | 2014-10-08 | (주)셀트리온 | 2 이상의 인플루엔자 ａ 바이러스 중화 결합 분자를 포함하는 조성물 |
| JPWO2015025900A1 (ja) * | 2013-08-23 | 2017-03-02 | 学校法人藤田学園 | 抗インフルエンザウイルス中和抗体 |
| CN105829589B (zh) * | 2013-11-07 | 2021-02-02 | 小利兰·斯坦福大学理事会 | 用于分析人体微生物组及其组分的无细胞核酸 |
| US20160304586A1 (en) * | 2013-12-05 | 2016-10-20 | Crucell Holland B.V. | Process for preparing influenza vaccines |
| WO2016010160A1 (ja) * | 2014-07-18 | 2016-01-21 | 国立感染症研究所長が代表する日本国 | 抗インフルエンザウイルス抗体及びその利用 |
| WO2016089181A1 (ko) * | 2014-12-05 | 2016-06-09 | (주)셀트리온 | 1 이상의 인플루엔자 바이러스 중화 결합 분자를 포함하는 애주번트 조성물 및 이를 포함하는 백신 조성물 |
| US20180008702A1 (en) * | 2014-12-05 | 2018-01-11 | Celltrion Inc. | Adjuvant composition containing at least one influenza virus neutralizing and binding molecule and vaccine composition containing same |
| TWI702229B (zh) | 2014-12-19 | 2020-08-21 | 美商再生元醫藥公司 | 流行性感冒病毒血球凝集素之人類抗體 |
| US10736956B2 (en) | 2015-01-23 | 2020-08-11 | Icahn School Of Medicine At Mount Sinai | Influenza virus vaccination regimens |
| US9890206B2 (en) * | 2015-08-20 | 2018-02-13 | Medigen Biotechnology Corporation | H1N1 flu virus neutralizing antibodies |
| WO2017083627A1 (en) | 2015-11-13 | 2017-05-18 | Visterra, Inc. | Compositions and methods for treating and preventing influenza |
| EP3419663A1 (en) | 2016-02-24 | 2019-01-02 | Visterra, Inc. | Formulations of antibody molecules to influenza virus |
| WO2017218624A1 (en) | 2016-06-15 | 2017-12-21 | Icahn School Of Medicine At Mount Sinai | Influenza virus hemagglutinin proteins and uses thereof |
| EP3498263B1 (en) | 2016-08-10 | 2023-11-29 | Celltrion Inc. | Stable liquid pharmaceutical preparation for anti-influenza virus antibody |
| US20180169780A1 (en) * | 2016-12-19 | 2018-06-21 | Anvil International, Llc | Cleanline threader |
| WO2018187706A2 (en) | 2017-04-07 | 2018-10-11 | Icahn School Of Medicine At Mount Sinai | Anti-influenza b virus neuraminidase antibodies and uses thereof |
| JP7403733B2 (ja) | 2017-09-04 | 2023-12-25 | 国立感染症研究所長 | インフルエンザｈａスプリットワクチンの製造方法 |
| SG11202006379UA (en) | 2018-01-26 | 2020-07-29 | Regeneron Pharma | Human antibodies to influenza hemagglutinin |
| TWI688653B (zh) * | 2018-01-30 | 2020-03-21 | 長庚醫療財團法人林口長庚紀念醫院 | 人源抗腸病毒７１型單株抗體的製法、產物及其應用 |
| EP3810634A4 (en) | 2018-06-21 | 2022-07-27 | Icahn School of Medicine at Mount Sinai | Mosaic influenza virus hemagglutinin polypeptides and uses thereof |
| MX2021000951A (es) | 2018-07-23 | 2021-06-23 | Sumitomo Pharma Co Ltd | Composición que contiene vacuna contra la influenza. |
| KR20200060969A (ko) | 2018-11-23 | 2020-06-02 | (주)셀트리온 | 인플루엔자 바이러스 질환을 치료하기 위한 투여 요법 |
| SG11202109566XA (en) | 2019-03-04 | 2021-10-28 | Japan As Represented By Director General Of Nat Institute Of Infectious Diseases | Method for preparing influenza ha split vaccine |
| CN113924147A (zh) | 2019-03-25 | 2022-01-11 | 威特拉公司 | 用于治疗和预防流感的组合物和方法 |
| EP3959216A4 (en) | 2019-04-24 | 2023-01-11 | Icahn School of Medicine at Mount Sinai | ANTI-INFLUENZA B VIRUS NEURAMINIDASE ANTIBODIES AND USES THEREOF |
| CN116367856A (zh) | 2020-09-08 | 2023-06-30 | 诺福金基因科技有限公司 | 针对甲型流感病毒的抗病毒组合物 |
| CN120965865B (zh) * | 2025-10-15 | 2026-01-16 | 内蒙古盛健生物科技有限责任公司 | 一种用于特异性治疗奶山羊羔羊口疮的抗体及其应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2637837A1 (en) | 2006-01-26 | 2007-08-09 | Hx Diagnostics, Inc. | Monoclonal antibodies binding to avian influenza virus subtype h5 haemagglutinin and uses thereof |
| CN101541832B (zh) * | 2006-09-07 | 2014-11-12 | 克鲁塞尔荷兰公司 | 能中和流感病毒h5n1的人结合分子及其应用 |
| CA2663388C (en) * | 2006-09-07 | 2017-01-17 | Crucell Holland B.V. | Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof |
| MX2010006148A (es) * | 2007-12-06 | 2011-02-23 | Dana Farber Cancer Inst Inc | Anti-cuerpos contra el virus de la influenza y metodos de uso de los mismos. |
| WO2009121004A2 (en) * | 2008-03-28 | 2009-10-01 | Sea Lane Biotechnologies, Llc | Neutralizing molecules to viral antigens |
| ES2662519T3 (es) * | 2008-07-25 | 2018-04-06 | Institute For Research In Biomedicine | Anticuerpos neutralizantes contra el virus de la gripe A y usos de estos |
-
2011
- 2011-03-07 US US13/583,529 patent/US9573991B2/en active Active
- 2011-03-07 CA CA2790949A patent/CA2790949C/en active Active
- 2011-03-07 CN CN201180013223.6A patent/CN102791734B/zh active Active
- 2011-03-07 EA EA201201116A patent/EA021977B1/ru not_active IP Right Cessation
- 2011-03-07 AU AU2011225044A patent/AU2011225044B2/en not_active Ceased
- 2011-03-07 JP JP2012556968A patent/JP5795340B2/ja active Active
- 2011-03-07 WO PCT/KR2011/001563 patent/WO2011111966A2/en not_active Ceased
- 2011-03-07 EP EP16175875.0A patent/EP3098236A1/en active Pending
- 2011-03-07 EP EP14181741.1A patent/EP2860190A3/en not_active Withdrawn
- 2011-03-07 KR KR1020110020061A patent/KR101297784B1/ko active Active
- 2011-03-07 MX MX2012010406A patent/MX338758B/es active IP Right Grant
- 2011-03-07 CA CA2849668A patent/CA2849668A1/en not_active Abandoned
- 2011-03-07 EP EP11753571.6A patent/EP2545074A4/en not_active Withdrawn
- 2011-03-07 EA EA201400855A patent/EA201400855A1/ru unknown
-
2012
- 2012-09-03 IL IL221760A patent/IL221760A/en active IP Right Grant
-
2013
- 2013-07-19 AU AU2013207641A patent/AU2013207641B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| JP5795340B2 (ja) | 2015-10-14 |
| EA201201116A1 (ru) | 2013-03-29 |
| KR101297784B1 (ko) | 2013-08-20 |
| CA2790949A1 (en) | 2011-09-15 |
| EP2545074A2 (en) | 2013-01-16 |
| CA2790949C (en) | 2017-08-01 |
| WO2011111966A2 (en) | 2011-09-15 |
| CN102791734B (zh) | 2014-10-15 |
| AU2011225044A1 (en) | 2012-09-20 |
| WO2011111966A3 (en) | 2012-04-05 |
| EP2860190A2 (en) | 2015-04-15 |
| CN102791734A (zh) | 2012-11-21 |
| AU2011225044B2 (en) | 2013-08-22 |
| EA021977B1 (ru) | 2015-10-30 |
| EP3098236A1 (en) | 2016-11-30 |
| EA201400855A1 (ru) | 2014-11-28 |
| AU2013207641B2 (en) | 2016-01-14 |
| US9573991B2 (en) | 2017-02-21 |
| MX2012010406A (es) | 2012-10-03 |
| KR20110102198A (ko) | 2011-09-16 |
| US20130004505A1 (en) | 2013-01-03 |
| EP2545074A4 (en) | 2014-01-08 |
| IL221760A (en) | 2016-07-31 |
| EP2860190A3 (en) | 2015-07-15 |
| JP2013527749A (ja) | 2013-07-04 |
| CA2849668A1 (en) | 2011-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX338758B (es) | Anticuerpos monoclonales humanos, derivados de celulas b humanas, y que tienen actividad neutralizante contra el virus de la influenza a. | |
| CY1124043T1 (el) | Εξουδετερωτικα αντισωματα του ανθρωπινου ιου της ανοσοανεπαρκειας και μεθοδοι χρησης αυτων | |
| PE20141398A1 (es) | Anticuerpos neutralizantes de citomegalovirus humano | |
| ES2670621T3 (es) | Anticuerpos que se unen a OX40 y sus usos | |
| PE20131403A1 (es) | Anticuerpos anti-ox40 y metodos de uso de los mismos | |
| CY1123145T1 (el) | Anti-cd40 αντισωματα | |
| CO6430469A2 (es) | Anticuerpos humanizados que se unen a cd19 y sus usos | |
| MX354101B (es) | FORMULACION PARA ANTICUERPO ANTI -A4ß7. | |
| PE20140247A1 (es) | Anticuerpos anti-cd38 | |
| GT201100023A (es) | Anticuerpos neutralizantes del virus anti - influenza a y usos de los mismos | |
| EA201991577A1 (ru) | Новые антитела против рецептора трансферрина человека, способные преодолевать гематоэнцефалический барьер | |
| ES2687282T3 (es) | Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos | |
| ES2776179T3 (es) | Anticuerpos dirigidos contra determinantes de la superficie de S. aureus | |
| PE20181270A1 (es) | Anticuerpo que neutraliza el virus respiratorio sincitial humano | |
| NZ605980A (en) | Anti-fap antibodies and methods of use | |
| PE20150002A1 (es) | Anticuerpos anti-fcrn | |
| PE20110345A1 (es) | Anticuerpos contra la il17 humana | |
| PE20141017A1 (es) | Anticuerpos del cea | |
| PH12016500859B1 (en) | Anti-human respiratory syncytial virus (rsv) antibodies and methods of use | |
| WO2012040562A3 (en) | Novel hiv-1 broadly neutralizing antibodies | |
| PE20142407A1 (es) | Formulacion de anticuerpos | |
| MX2014001374A (es) | Composicion farmaceutica para el tratamiento y/o prevencion de cancer. | |
| CR20120577A (es) | Anticuerpos hacia gdf8 humano | |
| MX2013009151A (es) | Inmunoterapia mejorada. | |
| PE20141568A1 (es) | Anticuerpos humanizados que reconocen la alfa-sinucleina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |